Inflammation Good, Inflammation Bad

Inflammation is frequently invoked in the context of hair loss — as a cause of androgenetic alopecia, as the mechanism by which immune conditions attack follicles, and paradoxically, as the supposed mechanism by which platelet-rich plasma (PRP) stimulates hair regrowth. If inflammation damages follicles, how can an inflammatory stimulus also restore them? The answer lies not in the word "inflammation" itself — a word too coarse to carry meaningful biological precision — but in the specific mediators involved, the duration and organisation of the inflammatory response, and whether the process is biologically configured to destroy or to repair. This article examines the evidence for both sides: the destructive cytokine-mediated inflammation that measurably harms the hair follicle, and the controlled wound-healing cascade induced by PRP that biases the follicular microenvironment toward regeneration rather than damage.

Abstract

Hair follicle biology is profoundly sensitive to its local immune microenvironment. The follicle normally exists under partial immune privilege — a state of attenuated inflammatory surveillance that protects its cycle from disruption. When this privilege collapses, or when chronic perifollicular inflammation accumulates, the consequences are well-characterised: pro-inflammatory cytokines including Tumour Necrosis Factor Alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6) push follicles prematurely into catagen, accelerate miniaturisation, damage the follicular stem cell niche, and in sustained cases can drive perifollicular fibrosis and permanent follicle loss. Platelet-rich plasma therapy, by contrast, does not produce this form of inflammation. It induces an acute, self-limiting wound-healing cascade characterised by the release of Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Transforming Growth Factor Beta (TGF-β), and Insulin-like Growth Factor 1 (IGF-1) — mediators that recruit reparative cells, promote angiogenesis, support dermal papilla activity, and may both prolong anagen and attenuate the maladaptive perifollicular inflammation underlying androgenetic alopecia. The apparent paradox — that inflammation causes hair loss while an "inflammatory" treatment repairs it — resolves when one recognises that biological outcomes are determined not by the label "inflammation" but by the specific molecular programme activated, its temporal organisation, and whether it carries a signal for resolution.

Part 1: The Hair Follicle as an Immunologically Privileged Structure

Immune Privilege and Why It Matters

The hair follicle is one of a small number of anatomical sites in the body — alongside the eye, brain, testis, and placenta — that maintain a state of relative immune privilege.¹ This means that certain components of the adaptive immune response, particularly cytotoxic T-cell activity and classical MHC class I antigen presentation, are actively suppressed within the follicle during the anagen (growth) phase. This suppression is not accidental: it is an evolved mechanism that protects the rapidly proliferating cells of the hair matrix and follicular unit from immune surveillance during a period of intense biological activity.

Immune privilege within the anagen follicle is maintained by a combination of immunosuppressive signals including α-melanocyte-stimulating hormone (α-MSH), transforming growth factor-β (TGF-β), and insulin-like growth factor-1 (IGF-1), as well as the physical barrier of the follicular epithelium and its specialised basement membrane.² Critically, the downregulation of MHC class I expression on follicular epithelial cells during anagen means that these cells are less visible to CD8+ cytotoxic T lymphocytes — reducing the risk of immune-mediated attack during the follicle's most vulnerable phase.

When immune privilege collapses — whether through injury, infection, autoimmune disease, or the progressive perifollicular microinflammation now recognised as a feature of androgenetic alopecia — the consequences for follicular cycling and survival can be severe.³ Understanding why requires examining what the follicle's local cytokine environment looks like under different pathological conditions.

Part 2: The Biology of Damaging Inflammation in Hair Loss

Perifollicular Microinflammation and Androgenetic Alopecia

Androgenetic alopecia (AGA) has traditionally been understood as a purely androgen-mediated process: DHT binds to the androgen receptor in dermal papilla cells, triggering the secretion of paracrine signals that progressively miniaturise susceptible follicles over successive hair cycles.⁴ This framing is accurate but incomplete. Histological studies of balding scalp have consistently demonstrated the presence of perifollicular lymphocytic infiltrates — accumulations of activated immune cells in the connective tissue sheath surrounding the follicle — in a substantial proportion of AGA specimens.⁵ This perifollicular microinflammation, while not the classical dense infiltrate of alopecia areata, represents a chronic low-grade inflammatory state that appears to worsen over time and correlates with degree of hair loss.

Crucially, this microinflammation is not merely an epiphenomenon of follicle miniaturisation — it appears to be a biologically active contributor to it. The pro-inflammatory cytokines produced within this perifollicular environment have measurable and well-characterised effects on follicle biology, effects that synergise with the androgen axis to accelerate the pathological process.^4,5

Tumour Necrosis Factor Alpha (TNF-α)

TNF-α is one of the most potent and pleiotropic pro-inflammatory cytokines in human biology, playing a central role in innate immune activation, apoptosis induction, and the orchestration of inflammatory responses to infection and injury. Within the hair follicle, its effects are predominantly destructive. The landmark in vitro work by Philpott and colleagues demonstrated directly that TNF-α applied to isolated human hair follicles significantly inhibits hair shaft elongation, with follicles entering catagen-like regression under cytokine exposure at concentrations commensurate with those found in inflammatory tissue.⁶ TNF-α mediates these effects through several mechanisms: it activates nuclear factor-kappa B (NF-κB) signalling within follicular cells — a master regulatory pathway that promotes inflammation and suppresses survival signals — and it induces apoptosis in the rapidly proliferating cells of the hair matrix through caspase-dependent pathways.

Beyond its direct effects on follicular keratinocytes, TNF-α upregulates the expression of MHC class I and class II molecules on follicular epithelial cells, effectively dismantling the immune privilege that protects the anagen follicle from immune-mediated attack.³ This collapse of follicular immune privilege creates a positive feedback loop: inflammatory cytokines damage immune privilege, making follicles more visible to autoreactive immune cells, which in turn produce more inflammatory cytokines. In the context of alopecia areata — where this mechanism is most clearly demonstrated — the result is rapid and dramatic follicle loss. In the more subtle setting of AGA-associated microinflammation, the same mechanism appears to operate at a lower amplitude, contributing to progressive miniaturisation over years rather than acute hair loss over weeks.

Interleukin-1 (IL-1α and IL-1β)

The IL-1 family includes two principal agonistic isoforms — IL-1α and IL-1β — that both signal through the same receptor (IL-1R1) and produce broadly similar downstream effects in the follicular microenvironment. Philpott's in vitro studies demonstrated that IL-1α and IL-1β, like TNF-α, potently inhibit hair follicle growth in isolated human follicles, with IL-1α being the more active isoform in this context.⁶ The mechanism involves IL-1R1-mediated activation of NF-κB and the downstream induction of cyclooxygenase-2 (COX-2), with consequent prostaglandin production that further amplifies the local inflammatory milieu.

IL-1 signalling within the follicle also promotes the local production of matrix metalloproteinases (MMPs), enzymes that degrade the extracellular matrix components of the follicular basement membrane and connective tissue sheath. Progressive degradation of this structural matrix — normally a stable scaffold that guides follicular regeneration through successive hair cycles — impairs the geometric precision with which a new hair follicle reconstructs itself after catagen. Over successive cycles of IL-1-mediated matrix degradation, the follicle's structural architecture deteriorates, contributing to the gradual miniaturisation that characterises androgenetic alopecia.⁴

IL-1β is also a potent inducer of catagen — the regression phase of the hair cycle. Follicles exposed to IL-1β in vitro show premature catagen entry, suggesting that elevated IL-1 signalling in the perifollicular microenvironment may directly shorten the anagen phase and accelerate cycling through regression, producing finer, shorter hairs with each successive cycle.⁶

Interleukin-6 (IL-6)

IL-6 occupies a distinctive position in the inflammatory cytokine network: it is simultaneously a pro-inflammatory mediator and, in certain contexts, an acute-phase protein with pleiotropic roles in tissue homeostasis. In the context of follicular biology, however, its predominant effect — particularly under conditions of chronic elevation — is disruptive. IL-6 signals through a membrane-bound receptor complex that activates the Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway, particularly STAT3.⁷ While STAT3 activation has roles in wound healing and tissue repair, chronic STAT3 signalling within the follicular unit is associated with impaired hair cycle progression and reduced follicle regenerative capacity.

IL-6 is produced in abundance by activated fibroblasts, mast cells, and macrophages — all of which are found in elevated numbers in the perifollicular infiltrates of androgenetic alopecia and scarring alopecia specimens.^5,8 Elevated IL-6 has been documented in both the serum and scalp tissue of patients with androgenetic alopecia compared to controls, suggesting that the perifollicular inflammatory microenvironment creates measurable systemic immune activation. In the scarring alopecias — primary cicatricial conditions such as lichen planopilaris and frontal fibrosing alopecia — IL-6 contributes to the fibrogenic cascade that ultimately replaces follicular tissue with collagen, permanently obliterating the follicular stem cell niche and eliminating the follicle's capacity for regeneration.⁸

The Collective Consequences: Five Mechanisms of Follicular Damage

The pro-inflammatory cytokines described above do not act in isolation — they interact with each other, with androgen signalling, and with the broader immune microenvironment to produce a coordinated programme of follicular damage that operates through five partially overlapping mechanisms:

Part 3: The Anatomy of Healing Inflammation — What PRP Actually Does

A Controlled Wound-Healing Cascade, Not Destructive Inflammation

Platelet-rich plasma (PRP) therapy involves injecting a concentration of the patient's own platelets — typically three to five times the normal blood concentration — into the scalp. Platelets, once activated at the injection site by contact with tissue and local thrombin, release the contents of their intracellular alpha granules: a complex mixture of growth factors, adhesion molecules, and signalling proteins that collectively constitute the biological programme of wound healing and tissue repair.¹⁰

This is an important distinction: PRP does not aim to create the kind of destructive, cytokine-mediated inflammation described in Part 2. It does not deliver TNF-α, IL-1, or IL-6. It induces a brief, controlled, self-limiting wound-healing cascade — a biological programme that is teleologically opposite to chronic inflammatory damage. Where destructive inflammation is disorganised, persistent, and driven by immune mediators that evolved to defend against infection, the wound-healing cascade is organised, temporally bounded, and driven by growth factors that evolved to rebuild damaged tissue. These are not two expressions of the same process — they are fundamentally different biological states that share only the linguistic label "inflammation" in lay usage.¹¹

Platelet-Derived Growth Factor (PDGF)

PDGF is among the most abundant growth factors in platelet alpha granules and is released in quantity upon platelet activation at the injection site. It exists as several isoforms (PDGF-AA, PDGF-BB, PDGF-AB), of which PDGF-BB is the most biologically active in the context of follicular stimulation. PDGF signals through tyrosine kinase receptors expressed on dermal papilla cells — the mesenchymal cells at the base of the hair follicle that serve as the primary inductive signal for hair follicle cycling and hair shaft production.¹²

By activating dermal papilla cells, PDGF supports the paracrine signalling axis through which dermal papilla cells instruct the overlying follicular epithelium to enter and sustain anagen. In vitro studies of dermal papilla cells show that PDGF exposure promotes cell proliferation and the upregulation of growth-promoting signalling pathways.¹² PDGF also recruits fibroblasts and other reparative cells to the treatment site — a key function in the early phase of wound healing that contributes to the structural repair of the perifollicular connective tissue sheath.

Vascular Endothelial Growth Factor (VEGF)

Follicle anagen is a metabolically intensive process: the rapidly proliferating cells of the hair matrix require abundant oxygen and nutrient delivery. This demand is served by a dense perifollicular capillary network that forms around active anagen follicles and regresses during catagen and telogen. VEGF is the primary angiogenic signal that drives the formation and maintenance of this perifollicular vasculature.

Elegant work by Yano and colleagues demonstrated directly that VEGF is both necessary and sufficient for normal hair follicle anagen maintenance in murine models: transgenic overexpression of VEGF in mouse skin produced follicles with increased vascularity and significantly accelerated hair regrowth after depilation, while VEGF blockade reduced follicle size and impaired anagen maintenance.¹³ PRP delivers VEGF — and stimulates local VEGF production — at the injection site, promoting perifollicular angiogenesis that enhances the oxygen and nutrient supply to follicles attempting to sustain or re-enter anagen. In the balding scalp, where perifollicular vascularity is often reduced compared to non-balding areas, this angiogenic stimulus may help restore the vascular infrastructure that active follicles require.¹⁴

Transforming Growth Factor Beta (TGF-β)

TGF-β presents the most biologically nuanced story in the PRP growth factor profile, because it is a mediator with well-established roles in both regeneration and fibrosis depending on context, concentration, duration of exposure, and the cell types receiving the signal. In the follicular literature, TGF-β1 produced by dermal papilla cells is a known inducer of catagen, promoting hair follicle regression at the end of the anagen phase — a normal part of the hair cycle.¹⁵ Chronic overexpression of TGF-β1 in the perifollicular microenvironment, meanwhile, contributes to the fibrogenic cascade in scarring alopecias.

Why then does TGF-β in PRP not simply promote catagen and fibrosis? The answer lies in the critical distinction between an acute, self-limiting pulse of TGF-β delivered in the context of a wound-healing cascade — alongside PDGF, VEGF, and IGF-1 — versus chronic, sustained TGF-β elevation in a pathological inflammatory microenvironment. In the wound-healing context, TGF-β serves as a potent recruiter of fibroblasts and macrophages to the repair site, drives the synthesis of extracellular matrix components that scaffold tissue regeneration, and activates the anti-inflammatory phenotype of tissue macrophages that resolves the wound response once repair is complete.^10,12 The temporal organisation and molecular context in which TGF-β signals determine whether the outcome is repair or fibrosis. Acute PRP-derived TGF-β in a wound-healing programme is configured for repair; chronic inflammatory TGF-β in a fibrogenic cascade is configured for scarring.

Insulin-like Growth Factor 1 (IGF-1)

IGF-1 is one of the most well-characterised positive regulators of hair follicle anagen. It is produced locally by dermal papilla cells and their surrounding fibroblasts, and signals through the IGF-1 receptor expressed on follicular keratinocytes to promote cell survival, proliferation, and anagen maintenance.¹⁶ Loss-of-function studies in mouse models confirm that IGF-1 signalling is required for normal hair cycle progression: mice with conditional deletion of IGF-1 receptor in the follicular epithelium show delayed anagen entry, reduced hair density, and impaired follicle growth.

PRP delivers IGF-1 both from platelet alpha granules and from the plasma fraction of the preparation, where the majority of circulating IGF-1 is present in bound form with insulin-like growth factor-binding proteins (IGFBPs) that protect it from rapid degradation and extend its local residence time.¹⁰ At the injection site, IGF-1 released from the platelet releasate and the plasma fraction provides a local anabolic signal to follicular keratinocytes and dermal papilla cells — one that promotes follicle survival, supports dermal papilla cell maintenance, and may help counteract the cytokine-mediated suppression of follicular growth signals that characterises the inflamed balding scalp.

Reparative Cell Recruitment and Downstream Effects

Beyond the direct effects of individual growth factors on follicular cell populations, PRP's wound-healing cascade recruits a broader cellular programme of repair. The chemotactic signals released by activated platelets attract monocytes, which differentiate at the treatment site into reparative (M2-phenotype) macrophages — cells configured for anti-inflammatory signalling, debris clearance, and the production of further growth factors that sustain tissue repair. This is mechanistically distinct from the pro-inflammatory (M1-phenotype) macrophages that characterise the chronic perifollicular infiltrates of androgenetic alopecia.¹¹

Multiple randomised controlled trials of PRP for androgenetic alopecia have now demonstrated measurable improvements in hair density, hair shaft diameter, and anagen-to-telogen ratio in treated areas compared to controls.^17,18 The clinical response is consistent with the biological effects described above: improved follicular vascularity, supported dermal papilla function, and — at least in responders — a shift in the follicular microenvironment toward conditions that sustain anagen rather than promote miniaturisation and regression.

Part 4: Resolving the Paradox — PRP May Work Against Harmful Inflammation

The Subtlety Most Commentaries Miss

The conventional framing of PRP as an "inflammatory stimulus" that happens to grow hair misses the most interesting aspect of its mechanism. PRP does not merely add a different type of inflammation on top of the maladaptive perifollicular microinflammation already present in the balding scalp. There is emerging evidence that PRP's wound-healing cascade may actively modulate the local immune microenvironment in ways that attenuate the harmful chronic inflammation that is damaging follicles.

The M2 macrophage phenotype recruited by PRP's platelet-derived signals produces IL-10 and TGF-β in a wound-healing context — cytokines that suppress the very M1 macrophage activation responsible for TNF-α and IL-1 production.¹⁹ In other words, PRP's downstream cellular programme may include anti-inflammatory components that counteract the perifollicular cytokine milieu driving miniaturisation. If this mechanism operates in the scalp — and the histological evidence from PRP-treated androgenetic alopecia suggests it may — then PRP's benefit is partly attributable not to its growth factor content per se, but to its capacity to redirect the local immune programme from a destructive toward a reparative phenotype.²⁰

This reframes the therapeutic logic of PRP entirely. The treatment does not succeed because it inflames the scalp. It may succeed, at least in part, because it temporarily overwhelms the pathological inflammatory signal with a biologically organised wound-healing programme — one that leaves the follicular microenvironment in a better state than it found it. A brief, controlled healing response that resolves is very different from chronic smouldering inflammation that does not.

The Paradox Resolved: A Taxonomy of Inflammation

The apparent contradiction — inflammation causes hair loss, yet an "inflammatory" treatment can restore it — resolves completely once the word "inflammation" is replaced with the mechanistic specificity the biology demands:

Bad inflammation damages follicles. The controlled healing cascade induced by PRP can stimulate repair — and may even help to correct the bad inflammation that is the underlying problem. These are not two points on the same spectrum; they are qualitatively different biological programmes that happen to share a word.

Clinical Implications

This biological framework has several practical implications for how PRP for hair loss should be understood and communicated.

Conclusion

The hair follicle is not simply a passive victim of inflammation — it is an actively immunoregulated structure whose cycle and survival depend on the precise character of its local immune microenvironment. Chronic perifollicular inflammation, mediated by TNF-α, IL-1, and IL-6, disrupts that environment in ways that are well-documented and mechanistically coherent: premature catagen induction, miniaturisation, stem cell niche damage, impaired cycling, and — in the most severe cases — irreversible fibrosis. These mediators evolved not to grow hair but to defend tissue against infection and injury, and when they accumulate chronically around follicles, the biological consequence is damage.

PRP therapy operates through an entirely different programme. Its platelet-derived growth factors — PDGF, VEGF, TGF-β, and IGF-1 — constitute the organised molecular signature of acute wound healing and tissue repair. They support dermal papilla activity, promote angiogenesis, recruit reparative cells, and sustain anagen. Critically, emerging evidence suggests that PRP's wound-healing cascade may actively attenuate the maladaptive perifollicular inflammation that is simultaneously damaging the follicles PRP seeks to repair. Far from being an inflammatory treatment that inexplicably grows hair, PRP may work precisely because it counterbalances harmful inflammation with a biologically superior healing signal.

The apparent paradox dissolves under biological scrutiny. What matters is not whether a stimulus is "inflammatory" in the colloquial sense, but what specific molecular programme it activates, for how long, and to what end. In hair biology as in most of medicine, the same category label can describe processes that are mechanistically, temporally, and clinically worlds apart.

References

1. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999;341(7):491–497. doi:10.1056/NEJM199908123410706
2. Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol. 2004;164(2):623–634. doi:10.1016/S0002-9440(10)63151-3
3. Ito T, Ito N, Saatoff M, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128(5):1196–1206. doi:10.1038/sj.jid.5701183
4. Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37(8–9):981–990. doi:10.1016/s0531-5565(02)00093-1
5. Mahé YF, Buan B, Billoni N, et al. Androgenetic alopecia and microinflammation. Int J Dermatol. 2000;39(8):576–584. doi:10.1046/j.1365-4362.2000.00023.x
6. Philpott MP, Sanders DA, Bowen J, Kealey T. Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. Br J Dermatol. 1996;135(6):942–948. doi:10.1111/j.1365-2133.1996.tb01896.x
7. Narimatsu M, Maeda H, Itoh S, et al. Tissue-specific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells. Mol Cell Biol. 2001;21(19):6615–6625. doi:10.1128/MCB.21.19.6615-6625.2001
8. Harries MJ, Paus R. The pathogenesis of primary cicatricial alopecias. Am J Pathol. 2010;177(5):2152–2162. doi:10.2353/ajpath.2010.100454
9. Cotsarelis G. Epithelial stem cells: a folliculocentric view. J Invest Dermatol. 2006;126(7):1459–1468. doi:10.1038/sj.jid.5700376
10. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91(1):4–15. doi:10.1160/TH03-07-0440
11. Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: a milieu of bioactive factors. Arthroscopy. 2012;28(3):429–439. doi:10.1016/j.arthro.2011.10.018
12. Li ZJ, Choi HI, Choi DK, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012;38(7 Pt 1):1040–1046. doi:10.1111/j.1524-4725.2012.02394.x
13. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409–417. doi:10.1172/JCI11317
14. Schiavone G, Raskovic D, Greco J, Abeni D. Platelet-rich plasma for androgenetic alopecia: a pilot study. Dermatol Surg. 2014;40(9):1010–1019. doi:10.1097/DSS.0000000000000062
15. Foitzik K, Lindner G, Mueller-Roever S, et al. Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J. 2000;14(5):752–760. doi:10.1096/fasebj.14.5.752
16. Weger N, Schlake T. Igf-I signalling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol. 2005;125(5):873–882. doi:10.1111/j.0022-202X.2005.23897.x
17. Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cells Transl Med. 2015;4(11):1317–1323. doi:10.5966/sctm.2015-0107
18. Alves R, Grimalt R. A randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatol Surg. 2016;42(4):491–497. doi:10.1097/DSS.0000000000000665
19. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci. 2008;13:3532–3548. doi:10.2741/2947
20. Giordano S, Romeo M, Lankinen P. Platelet-rich plasma for androgenetic alopecia: does it work? Evidence from meta analysis. J Cosmet Dermatol. 2017;16(3):374–381. doi:10.1111/jocd.12331